Steven Cohen Verona Pharma PLC Transaction History

Point72 Asset Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$53.9 - $98.68 $1.31 Million - $2.39 Million	24,256 Added 25.72%	118,578 $11.2 Million
Q1 2025 May 15, 2025	SELL	$44.81 - $69.63 $27.6 Million - $42.9 Million	-616,685 Reduced 86.73%	94,322 $5.99 Million
Q4 2024 Feb 14, 2025	BUY	$28.71 - $47.02 $20.4 Million - $33.4 Million	711,007 New	711,007 $33 Million
Q1 2023 May 15, 2023	SELL	$18.06 - $25.27 $4.37 Million - $6.11 Million	-241,700 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$9.84 - $26.13 $2.38 Million - $6.32 Million	241,700 New	241,700 $6.32 Million

273

76.9M

686K

442K

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $6.52B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.